PA-GROVARA
19.5.2022 13:02:12 CEST | Business Wire | Press release
Grovara , the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC) , a permanent wholesale market that facilitates business between international buyers and sellers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/
The partnership will integrate Grovara’s first-to-market digital global trading platform with DGC’s one-of-a-kind physical marketplace, providing unprecedented speed, reliability, and growth potential for DGC’s global wholesale buyers and sellers.
Grovara will leverage its international B2B online marketplace with DGC’s state-of-the-art showroom ecosystem for wholesale food, home furnishings, and fashion trade to supercharge CPG brands’ global distribution. Grovara’s digital platform streamlines and automates global wholesale trade, enabling buyers to find and manage suppliers and sellers while showcasing and selling goods online and managing fulfillment.
“The future of trade is digital, with a human touch. Our game-changing global marketplace will help bring Dubai Global Connect’s community of brands and buyers online,” says Grovara Co-Founder and CEO Abu Kamara. “Our technology is a turbo booster for international trade, and coupled with DGC’s state-of-the-art, bespoke physical showroom marketplace, Dubai is ready to be the launch pad.”
DGC’s facility will be one of the highlights of fast-growing Dubai South, the largest single urban master development in Dubai. Dubai South is being developed as an aviation and logistics ecosystem including a multi-modal transport infrastructure connecting air, land, and sea, and planned residential and commercial developments. DGC is located between Al Maktoum International Airport, which will be the world’s largest airport when construction is complete, and Jebel Ali Port, the Middle East’s busiest port.
With 2.5 billion people within a four-hour flight and 5 billion within an eight-hour flight, Dubai is globally recognized as an ideal place to live, work and play, while also offering transparent, business-friendly free-zone regulation across the country. The Dubai South Free Zone fosters ingenuity, offers ease of doing business, and provides comprehensive services that enable 100% foreign ownership and income and personal tax exemption.
Grovara will be the digital global wholesale option for those new businesses looking for buyers and sellers, with easy discovery, pricing, and purchasing that saves time and cost while delivering better performance via a curated marketplace. Sellers rely on Grovara’s automated export and operations document managers and achieve faster sales and brand valuations by selling to more customers.
“Our technology and in-country expertise will make it even easier for buyers and sellers from across the entire region to meet halfway in Dubai, where they’ll find all the support they need to grow,” says Grovara Sales Director Eugenia Schlitter.
DGC offers a number of physical spaces and services for brands and buyers, like showrooms, boutique offices, secure self-storage units with direct access to showrooms, and a smart service center offering a one-stop shop for a variety of business services. DGC is also planning a lavish auditorium, innovation hub, entrepreneurship center, and a year-round program of industry-specific programming.
“We are pleased to welcome Grovara to the Dubai Global Connect community here in Dubai,” says DGC’s Head of Business Development Paul Boots. “Grovara will be able to tap into DGC’s year-round physical showroom ecosystem and showcase some of the great brands available on their platform.
“Dubai is the natural gateway to the emerging markets, and the combination of Grovara and DGC will enable brands to expand their reach to a global buying audience, through Dubai. Partnerships such as these will further support DGC’s ambition to make Dubai a place of reference for the international B2B food trade, and we look forward to supporting them with the growth of their business.”
ABOUT GROVARA
Grovara enables an easy global wholesale experience as the first-to-market online marketplace supporting thousands of CPG products for export/import in more than 50 countries. With offices in Philadelphia, Mexico, and Dubai, Grovara facilitates global exporting and importing with a lightweight, tech-driven platform that provides automation and intelligence-based tools. Grovara leverages visibility, discovery, and an intuitive user experience to deliver easy transacting and management, creating a streamlined pathway to dynamic global growth potential. For more information or to join the curated ecosystem, please visit Grovara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
